Dr. Crowe envisions a future where antibody manufacturing is decentralized. A device, similar to a 3D printer, could download a specific antibody "recipe" and produce it on-site at a pharmacy or even in a home, revolutionizing rapid response and personalized medicine.

Unlike traditional approaches, Immunethep's vaccine doesn't kill bacteria. Instead, it neutralizes a virulence mechanism bacteria use to shut down the immune system. This restores the body's natural ability to fight infection, a novel strategy analogous to checkpoint inhibitors in oncology.

Infinimmune’s platform bypasses traditional discovery methods by reading antibodies directly from human memory B cells. The core insight is that the immune system has already spent a lifetime selecting and validating the most effective antibodies, providing a superior, de-risked starting point for new human therapeutics.

Contrary to the popular belief that antibody development is a bespoke craft, modern methods enable a reproducible, systematic engineering process. This allows for predictable creation of antibodies with specific properties, such as matching affinity for human and animal targets, a feat once considered a "flight of fancy."

Unlike vaccines requiring a patient's immune system to generate antibodies, Cidara's CD388 is a long-acting antiviral drug. It provides direct, passive protection by targeting a non-mutating part of the flu virus, making it effective for the millions of people with weakened immune systems who don't respond well to traditional shots.

The debate isn't about peptides replacing antibodies but about combining them. The future lies in hybrid therapeutics, such as grafting peptides into antibody CDRs or creating fusions that use a peptide for optimal target binding and an antibody scaffold for effector functions, half-life extension, and stability.

De novo design is not a magic bullet, but it's a powerful new tool. Major pharmaceutical companies report it successfully generates binders for difficult targets where conventional methods like immunization have failed, effectively closing critical gaps in the discovery pipeline.

Unlike traditional therapies, the safety of multi-specific antibodies cannot be optimized later via dose adjustments. Critical safety profiles are determined at the initial design stage, and early flaws can prevent a molecule from ever reaching therapeutically effective doses.

New drug formulations, like those for HIV prevention or cholesterol, create an internal depot that releases medicine over months. This dramatically improves efficacy by solving the massive problem of patient non-adherence to daily pills, representing a major shift in managing chronic conditions.